Daniel Lembo
Family · Lancaster, PANPI 1497463152
Payments from drug & device makers
Across 94 payments — averaging $21.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$462
- AstraZeneca$363
- AbbVie$307
- Astellas Pharma US Inc$167
- Pfizer$142
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$127
- plus $487 from 15 others
What the payments were for
- Food & beverage$2,055100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 19 | $462 |
| AstraZeneca | 17 | $363 |
| AbbVie | 15 | $307 |
| Astellas Pharma US Inc | 6 | $167 |
| Pfizer | 7 | $142 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $127 |
| Lilly USA, LLC | 5 | $93 |
| Phathom Pharmaceuticals, Inc. | 3 | $57 |
| GSK | 2 | $44 |
| Lundbeck LLC | 2 | $40 |
| Boehringer Ingelheim | 2 | $39 |
| Kowa Pharmaceuticals America, Inc. | 2 | $35 |
| Exact Sciences | 1 | $27 |
| Actelion Pharmaceuticals US, Inc. | 1 | $26 |
| Merck | 1 | $24 |
| Viatris Specialty LLC | 1 | $23 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| Scpharmaceuticals Inc. | 1 | $16 |
| Bayer | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $14 |
How this compares
$2,055 in reported general payments places this provider in the 80th percentile of 4,717 family providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Montelukast Sodium | 17 | $363 |
| Pantoprazole Sodium | 17 | $318 |
| Atorvastatin Calcium | 22 | $236 |
| Omeprazole | 11 | $140 |
| Metformin Hcl | 14 | $123 |
| Losartan Potassium | 15 | $104 |
| Levothyroxine Sodium | 11 | $102 |
| Lisinopril | 17 | $87 |
| Amlodipine Besylate | 16 | $58 |
Paid to pharmacies, not to this prescriber.
Other family in Lancaster
- Heidi Kling-NewnamLancaster$30K
- Kathleen ScholzPittsburgh$397K
- Shannon FitzgeraldAllison Park$370K
- Stephanie HarshbargerCamp Hill$317K
- Whitney BowlesFort Washington$253K
- Kweilynn GreenePittsburgh$139K
- Jessica LindenbergerPittsburgh$131K
- Kami NestlerWilkes Barre$129K
- Bethany ThomasPhiladelphia$126K
- Margaret RosenzweigPittsburgh$89K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.